| Overall survival | Progression-free survival | ||||
---|---|---|---|---|---|---|
Risk factor | HR | 95 % CI | p-value | HR | 95 % CI | p-value |
Gender female vs male | 1.016 | 0.47–2.19 | 0.967 | 0.960 | 0.48–1.94 | 0.911 |
Age | 0.966 | 0.49–1.89 | 0.921 | 0.862 | 0.45–1.64 | 0.650 |
>57 vs ≤57 | ||||||
Clinical stage | 5.699 | 1.35–24.09 | 0.018 | 3.353 | 1.15–9.77 | 0.027 |
III/IV vs I/II | ||||||
Tobacco current vs. never | 0.687 | 0.15–3.15 | 0.629 | 0.431 | 0.12–1.49 | 0.184 |
Tobacco former vs. never | 1.261 | 0.23–6.88 | 0.789 | 0.877 | 0.21–3.60 | 0.856 |
Alcohol current vs never | 0.786 | 0.28–2.18 | 0.644 | 1.261 | 0.50–3.16 | 0.621 |
Therapy1 radiochemo vs surgery | 0.953 | 0.46–1.98 | 0.897 | 0.798 | 0.40–1.60 | 0.524 |
HPV status2 related vs non-related | 0.404 | 0.17–0.96 | 0.041 | 0.305 | 0.13–0.70 | 0.005 |
Subgroup | 0.303 | 0.14–0.63 | 0.002 | 0.395 | 0.20–0.77 | 0.007 |
ALDH1A2highCRABP2high vs others |